关键词:

伏诺拉生, 质子泵抑制剂, 幽门螺杆菌

Abstract:

Objective To investigate the clinical effect and safety of vonolaxan combined with amoxicillin and clarithromycin for seven⁃day eradication of Helicobacter pylori（Hp）. Methods A total of 200 patients with Hp infection diagnosed in Dongguan Songshan Lake Tungwah Hospital from June 2021 to December 2021 were selected and randomly divided into a study group of 100 cases and a control group of 100 cases. The study group received Vonolaxan combined with amoxicillin and clarithromycin triple therapy for seven days ，while the control group received standard quadruple therapy for 2 weeks. All patients received carbon 13 breath test again after at least 4 weeks of drug. The general data，adverse reactions，Hp eradication rate and cost of the two groups of patients were compared. Results The number of cases in the study group and control group were 18 and 17 due to loss to follow⁃up and drop out of the study，respectively. In the end，82 samples in the study group and 83 samples in the control group were obtained. There was no statistical difference in the general data of age and gender between the two groups（P > 0.05）. In terms of adverse reactions，the overall incidence rate of the study group was 7.3%， compared with 12.0% of the control group，the difference was not statistically significant（χ2 = 1.054，P = 0.305）. In the study group，the eradication rate of Hp was 74.0%（74/100）by intention to treat（ITT）analysis and 90.2% （74/82）by per protocol（PP）analysis. In the control group，the eradication rate of Hp was 72.0%（72/100）by ITT analysis and 86.7%（72/83）by PP analysis. There was no significant difference between the two groups in the eradication rate of Hp by ITT（χ2 = 0.101，P = 0.750）and PP analysis（χ2 = 0.495，P = 0.482）（P > 0.05）. Conclusions Vonolaxan combined with amoxicillin and clarithromycin triple therapy for seven days is effective and safe in eradicating Hp，which is worthy of widespread clinical promotion.

Key words: vonolaxan,  , proton pump inhibitor,  , helicobacter pylori